Clinical Endocannabinoid Deficiency: Could You Be Running Low?

The Question Medicine Has Been Avoiding

You’ve been to the doctor. Multiple doctors, probably. You’ve described the crushing migraines that arrive with no warning and leave you horizontal for two days. The full-body ache that makes waking up feel like punishment. The gut that twists without any food sensitivity or structural cause anyone can identify. And every time, after every test, you’ve walked away with the same answer: We’re not sure what’s causing this. Here’s another medication to try.

This is the experience of tens of millions of people living with conditions like migraine, fibromyalgia, and irritable bowel syndrome (IBS) — disorders that lack clear diagnostic biomarkers, frequently co-occur in the same individuals, and have historically been dismissed as psychosomatic or “functional.” Standard pharmacological approaches often provide partial relief at best.

But what if these conditions share a common underlying mechanism — one that conventional medicine has largely overlooked? That’s the central argument behind Clinical Endocannabinoid Deficiency (CED), a theory first proposed by neurologist and pharmacologist Dr. Ethan B. Russo in 2001 and significantly expanded in a landmark 2016 review in Cannabis and Cannabinoid Research [Russo, 2016]. The hypothesis is deceptively simple: just as Alzheimer’s disease involves acetylcholine deficiency and Parkinson’s involves dopamine deficiency, certain chronic conditions may be rooted in a deficiency of the body’s own endocannabinoid signaling.

And the evidence backing it has been quietly accumulating for over two decades.

What Is Endocannabinoid Tone?

To understand CED, you first need to grasp the concept of endocannabinoid tone — a term Russo uses to describe the overall functional output of the endocannabinoid system (ECS).

The ECS is a vast, body-wide signaling network that helps maintain homeostasis across virtually every major physiological system. It operates through two primary endocannabinoids — anandamide (AEA) and 2-arachidonoylglycerol (2-AG) — that are produced on demand in tissues throughout the body. These molecules bind to cannabinoid receptors, primarily CB1 receptors (densely expressed in the brain and central nervous system) and CB2 receptors (found in immune cells and peripheral tissue), to regulate:

• Pain perception and central sensitization
• Mood, anxiety, and stress response
• Sleep architecture
• Digestion and gut motility
• Immune function and inflammation
• Appetite and metabolic rate

Endocannabinoid tone reflects all of this at once: the levels of AEA and 2-AG circulating in the system, how efficiently they’re produced and broken down (by enzymes like FAAH and MAGL), and how dense and sensitive the CB1/CB2 receptor landscape is at any given time. When tone is robust, the system acts as a finely tuned homeostatic regulator. When tone is chronically low, Russo’s theory predicts a predictable cascade of dysfunction across exactly the systems the ECS governs most — pain, digestion, mood, and sleep [Russo, 2016].

This is not metaphor. Russo’s 2016 paper states it plainly: “If endocannabinoid function were decreased, it follows that a lowered pain threshold would be operative, along with derangements of digestion, mood, and sleep.”

The Origin of the Theory

Russo first articulated the CED concept in 2001 and published a more thorough exploration in 2004 in Neuroendocrinology Letters [Russo, 2004]. The initial framework was built on three observational pillars:

1. Genetic and comorbid overlap: Migraine, fibromyalgia, and IBS occur together in the same patients at rates far exceeding chance. If they’re distinct disorders with distinct mechanisms, this clustering is hard to explain. If they share an upstream deficit in ECS function, the co-occurrence becomes predictable.

2. Symptom pattern coherence: All three conditions involve hyperalgesia (heightened pain sensitivity), central sensitization (the nervous system becoming amplified in its pain response), disrupted sleep, mood dysregulation, and autonomic dysfunction — precisely the domains the ECS normally regulates.

3. Cannabinoid treatment response: Historical and emerging clinical reports showed that cannabis and cannabinoid-based medicines provided meaningful relief for migraine, fibromyalgia, and IBS in ways that standard pharmacotherapy often could not match.

The 2004 paper was notable but lacked hard biochemical data. Russo himself acknowledged this. The 2016 revisitation was different — by then, objective evidence had begun to emerge.

What the Evidence Now Shows

Migraine: Lower Anandamide in the Cerebrospinal Fluid

The most direct biochemical evidence supporting CED comes from migraine research. A landmark study by Sarchielli et al. found statistically significant reductions in anandamide levels in the cerebrospinal fluid (CSF) of chronic migraine patients compared to controls [Sarchielli et al., 2007]. This is important because CSF reflects central nervous system biochemistry directly — not peripheral metabolic noise.

Russo’s 2016 review contextualizes this finding within the broader neuroscience of migraine. Anandamide is tonically active in the periaqueductal gray (PAG), a brainstem region that functions as the brain’s primary pain-modulation hub and is considered a key migraine generator. Reduced anandamide in this region would predictably lower the threshold at which pain signals are amplified rather than suppressed.

Additionally, AEA interacts with serotonin receptors in ways directly relevant to migraine: it potentiates 5-HT1A receptors (the target of triptans) and inhibits 5-HT2A receptors. A deficiency in AEA would compromise this serotonin-modulating function and help explain why standard triptan therapy fails in a significant subset of migraineurs [Russo, 2016].

Cannabis treatment data adds further weight. A retrospective study of medical cannabis patients with migraine found a 51.4% reduction in monthly migraine frequency following treatment — a magnitude of effect that outpaces most pharmaceutical prophylactics [Rhyne et al., 2016].

Fibromyalgia: A Central Sensitization Condition with ECS Fingerprints

Fibromyalgia is now broadly understood as a central sensitization disorder — a state in which the central nervous system becomes hyperactivated and amplifies pain signals disproportionately to any tissue injury. Widespread pain, fatigue, cognitive impairment (“fibrofog”), and sleep disturbances are its hallmarks.

A 2025 systematic review in Frontiers in Medicine confirmed what Russo had long argued: “The notion that fibromyalgia might be linked to a deficiency in the ECS has attracted significant interest in recent years, providing a potential explanation for the symptomatology associated with this chronic pain condition” [García-Domínguez, 2025]. The review highlighted evidence that ECS dysregulation contributes directly to the increased pain sensitivity and sleep disturbances characteristic of fibromyalgia, and that cannabinoid receptor activity in fascial tissue — the connective tissue network where many fibromyalgia patients report diffuse pain — may play a previously underappreciated role [Fede et al., 2016, cited in García-Domínguez, 2025].

CB1 receptors are expressed throughout the spinal cord and in descending pain pathways that normally suppress pain transmission. A deficiency in endocannabinoid tone in these circuits would predictably produce the widespread hyperalgesia and central sensitization that define fibromyalgia — and explain why it presents without any detectable peripheral tissue damage [Russo, 2016].

IBS: The Gut-Brain-ECS Axis

Irritable bowel syndrome presents a compelling case for CED from a different angle: the gut.

The gastrointestinal tract is densely innervated by the enteric nervous system (ENS), often called the “second brain,” and both CB1 and CB2 receptors are expressed throughout the gut in abundance. Endocannabinoids play a critical role in regulating gut motility, visceral pain sensitivity, secretion, and inflammation. CB1 activation slows gut transit and reduces visceral hyperalgesia — two of the primary dysfunctions in IBS [Russo, 2016].

A 2024 review in Nutrition in Clinical Practice further documented how the ECS and gut microbiome interact in bidirectional ways: dysbiosis (imbalanced gut bacteria) can reduce endocannabinoid signaling, while reduced endocannabinoid tone may impair gut barrier function [Russell et al., 2024]. This creates a potential feedback loop that helps explain why IBS is both so hard to treat pharmacologically and so responsive to interventions — including cannabis — that restore endocannabinoid function.

The symptom overlap with migraine and fibromyalgia in the same individuals is, again, exactly what CED theory would predict: multiple organ systems governed by the ECS all manifesting dysfunction simultaneously.

Beyond the Big Three: Expanding Evidence

Russo’s 2016 review extended the CED framework to several additional conditions where ECS dysfunction has been documented or plausibly implicated:

• Post-Traumatic Stress Disorder (PTSD): Advanced fMRI and PET imaging studies have demonstrated ECS hypofunction in PTSD — specifically, reduced CB1 receptor availability in the amygdala and prefrontal cortex, the circuits responsible for fear extinction [Russo, 2016]. This aligns with the well-known role of the ECS in emotional memory processing and explains the mounting evidence for cannabinoid-based PTSD therapy.

• Depression: A 2024 systematic review found that lower anandamide concentrations are associated with anxiety symptoms, and that peripheral endocannabinoid levels track meaningfully with depression severity and chronicity [Hindocha et al., 2024]. The correlation between reduced FAAH enzyme activity (which means less anandamide breakdown — counterintuitively suggesting an adaptive upregulation) and certain patterns of AUD and MDD further implicates ECS dysregulation in mood disorders.

• Multiple Sclerosis and Huntington’s Disease: Both conditions show documented ECS dysfunction, and both have seen the most regulatory traction for cannabinoid-based treatments. Sativex (nabiximols), a THC/CBD oromucosal spray, has regulatory approval in multiple countries for MS spasticity — a pharmaceutical acknowledgment of ECS-mediated pathology.

• Motion Sickness and Nausea: The dorsal vagal complex, which governs nausea and vomiting responses, is rich in CB1 receptors. Deficient endocannabinoid tone in this region may explain the heightened motion sickness and nausea susceptibility that co-occurs with migraine.

Why This Theory Matters Clinically

The CED framework represents a paradigm shift in how we think about treatment-resistant conditions. Rather than asking “what disease does this patient have, and what drug treats that disease?”, it asks: “is this patient’s endocannabinoid tone deficient, and what interventions restore it?”

This reframing has several practical implications.

First, it explains comorbidity. The well-documented tendency of migraine, fibromyalgia, IBS, PTSD, and depression to cluster in the same individuals — and to share demographic patterns (higher prevalence in women, connection to childhood adverse events, stress-sensitivity) — is elegantly explained by a single upstream deficit rather than six separate bad-luck diagnoses.

Second, it validates the patient experience. Millions of people with these conditions have been explicitly or implicitly told their symptoms are psychosomatic, exaggerated, or drug-seeking. CED provides a coherent biological mechanism that demands these conditions be taken seriously as physiological — not psychological — disorders with a measurable substrate.

Third, it opens genuine therapeutic avenues. If CED is real and measurable, it can potentially be corrected — through targeted supplementation, dietary optimization, lifestyle interventions, and carefully chosen cannabinoid therapies.

How Endocannabinoid Tone Can Be Influenced

This is where the science becomes directly actionable. Russo’s 2014 collaboration with McPartland and Guy produced a systematic review of interventions that upregulate the ECS — and the results span lifestyle, nutrition, and pharmacology [McPartland et al., 2014].

Dietary Interventions

Endocannabinoids AEA and 2-AG are synthesized from omega-6 polyunsaturated fatty acids (PUFAs), specifically arachidonic acid. But the ratio of omega-6 to omega-3 fatty acids in the diet profoundly affects endocannabinoid balance. Preclinical research shows that omega-3 PUFA deficiency elevates 2-AG levels in the brain (likely a compensatory response), while enrichment with omega-3s helps normalize ECS signaling [Watanabe et al., 2003, cited in Russell et al., 2024].

Practical implications:

• The Mediterranean diet — rich in omega-3s from fish, olive oil, and nuts — is associated with lower omega-6/omega-3 ratios and improved ECS function [Russell et al., 2024].
• Reducing excess omega-6 intake (processed seed oils) may help restore ECS balance.
• Some research suggests that dark chocolate and black truffles contain trace amounts of anandamide or anandamide precursors, though the clinical significance is modest.

Exercise

Aerobic exercise is one of the most potent natural ECS upregulators known. The famous “runner’s high” was long attributed to endorphins, but research now attributes much of it to elevated anandamide levels [Fuss et al., 2015]. Regular moderate-intensity exercise has been shown to increase CB1 receptor sensitivity and baseline endocannabinoid tone over time — directly relevant for patients with fibromyalgia and migraine who often experience symptom relief from consistent, low-impact movement.

Stress Reduction

Chronic psychological stress is a major suppressor of endocannabinoid tone. Acute stress elevates 2-AG transiently (a protective response), but chronic stress depletes both AEA and 2-AG and downregulates CB1 receptors over time [McPartland et al., 2014]. Mindfulness meditation, yoga, adequate sleep, and social connection all support ECS function — not through any direct pharmacological mechanism, but through the chronic stress load they reduce.

Cannabis and Cannabinoid Supplementation

If CED involves chronically low AEA and 2-AG, plant-derived cannabinoids offer one mechanism for supplementation — though the relationship is nuanced.

THC directly activates CB1 and CB2 receptors, compensating for deficient endocannabinoid tone in the short term. This is the most plausible pharmacological explanation for why migraine and fibromyalgia patients report symptomatic relief from cannabis that exceeds what conventional medications provide. For these conditions, strains in the Relaxing High family — typically indica-leaning with significant terpene depth — are most commonly reported to reduce pain and improve sleep in patient surveys.

CBD operates differently. It inhibits FAAH, the enzyme that breaks down anandamide — meaning CBD doesn’t add cannabinoids to the system directly, but prevents the body from degrading its own. For patients sensitive to THC’s psychoactive effects or concerned about intolerance, CBD-dominant products represent a gentler approach to supporting endocannabinoid tone. High-CBD strains and the Balancing High family are relevant here.

CBG shows early promise as a FAAH inhibitor as well, with potential anti-inflammatory effects relevant to gut-ECS pathology in IBS.

The key point — and Russo is careful to emphasize this — is that the goal of cannabinoid therapy in CED is not to get high. It’s to restore a biological deficit in a system that underpins basic wellbeing. Russospeaks of “a gentle pharmacological nudge” rather than a sledgehammer — a framing that aligns well with microdosing approaches and the use of full-spectrum products that engage the entourage effect across multiple cannabinoids and terpenes.

The Scientific Debate: Where CED Still Needs Work

Intellectual honesty demands acknowledging what the CED theory does not yet have.

No validated diagnostic test exists. CSF anandamide measurement is the closest thing to a biomarker, but lumbar punctures are invasive and impractical for routine clinical use. Blood and urine endocannabinoid levels don’t reliably reflect CNS tone. Until a non-invasive test is developed, CED cannot be formally diagnosed — only inferred.

Causality vs. correlation remains uncertain. Does low endocannabinoid tone cause migraine and fibromyalgia? Or do the chronic pain and stress of these conditions deplete endocannabinoid tone over time? Russo acknowledges this bidirectionality as an unresolved question.

Randomized controlled trial data on cannabinoid therapy for CED conditions remains limited. Most evidence comes from observational studies, patient surveys, and case series. The regulatory challenges of cannabis research have historically prevented large-scale RCTs — though this is slowly changing as more countries and states create research pathways.

Individual variability is substantial. Genetic polymorphisms in the FAAH gene (which affect AEA breakdown rates), CNR1 (the gene encoding CB1 receptors), and other ECS components mean that “endocannabinoid tone” is not a single uniform quantity — it’s a highly individual characteristic. What constitutes deficiency for one person may be normal range for another.

None of these limitations invalidate CED as a framework. They identify it accurately as a well-supported, mechanistically coherent hypothesis that awaits the formal clinical infrastructure to be rigorously tested — a situation common in any field where the biology outpaces regulatory and funding structures.

Could You Be Running Low?

There’s no blood test you can order, no definitive checklist. But the CED framework does offer a useful lens for self-reflection — especially for anyone who has experienced the exhausting loop of treatment-resistant symptoms, normal diagnostic workups, and the gnawing suspicion that something systemic is being missed.

The symptom clusters most consistent with CED, per Russo’s framework, include:

• Recurring migraine or chronic headache without clear trigger identification
• Widespread musculoskeletal pain without structural explanation (fibromyalgia-pattern)
• Functional bowel symptoms — alternating constipation/diarrhea, visceral pain, without IBD pathology
• Non-restorative sleep — waking unrefreshed regardless of hours slept
• Mood dysregulation — anxiety, low mood, heightened stress reactivity
• Multiple co-occurring conditions from the above list

This is not a diagnostic tool. But if this cluster describes your experience, and if conventional medicine has struggled to help you, the CED framework gives you a scientifically grounded reason to discuss endocannabinoid function with your healthcare provider — and to explore whether lifestyle interventions and cannabinoid-based approaches deserve a place in your care plan.

The ECS, Russo argues, operates as a homeostatic regulator that “sometimes requires a gentle pharmacological nudge, rather than a hammer.” That nudge can take many forms. The research, increasingly, is pointing toward the fact that for some people, it may be exactly what’s been missing all along.

Key Takeaways

• Clinical Endocannabinoid Deficiency (CED) is a hypothesis, first proposed by Dr. Ethan B. Russo in 2001, that chronic endocannabinoid tone insufficiency underlies treatment-resistant conditions including migraine, fibromyalgia, and IBS.
• Endocannabinoid tone reflects the systemic output of the ECS — determined by anandamide and 2-AG levels, their synthesis and degradation enzymes, and cannabinoid receptor density.
• Objective evidence has accumulated: CSF anandamide is measurably lower in chronic migraine patients; PET imaging shows CB1 hypofunction in PTSD; fibromyalgia research increasingly points to ECS dysregulation as a core mechanism.
• The conditions linked to CED cluster together in the same patients because they share a common upstream biological deficit — not because they are psychosomatic.
• Endocannabinoid tone can be supported through omega-3-rich diet, regular aerobic exercise, chronic stress reduction, and targeted cannabinoid use (THC for direct receptor activation, CBD/CBG for FAAH inhibition).
• CED lacks a clinical diagnostic test — it remains a well-evidenced hypothesis rather than a formal diagnosis, and RCT data on cannabinoid therapy for these conditions is still emerging.

FAQs

Is CED a real, accepted medical diagnosis?

Not yet. CED is a well-supported scientific hypothesis with growing objective evidence, but it is not currently a formal clinical diagnosis. There is no standardized diagnostic test, and it has not yet been incorporated into mainstream medical guidelines. It remains an active area of research.

Which conditions are most associated with CED?

Russo’s work focuses primarily on migraine, fibromyalgia, and IBS as having the strongest evidence for CED involvement. He also discusses PTSD, depression, motion sickness, anorexia nervosa, multiple sclerosis, and Huntington’s disease as conditions where ECS dysfunction has been documented.

Can CBD help with CED?

CBD inhibits FAAH, the enzyme that degrades anandamide — meaning it helps preserve the body’s own endocannabinoid levels rather than adding exogenous cannabinoids. This is one pharmacological mechanism by which CBD may support endocannabinoid tone. However, clinical evidence specifically for CBD as a CED treatment remains limited and largely anecdotal.

What is the best cannabis strain for CED-related conditions?

There is no universally “best” strain. Different conditions and different individuals respond differently. Patients with chronic pain conditions often report benefit from indica-leaning strains in the Relaxing High family, while those seeking daytime function without sedation may prefer balanced hybrids in the Balancing High family. Starting low and working with a knowledgeable dispensary is recommended.

How do omega-3 fatty acids affect the endocannabinoid system?

Endocannabinoids are synthesized from polyunsaturated fatty acids. The ratio of omega-6 to omega-3 fats in the diet affects this balance. Diets rich in omega-3s (from fatty fish, flaxseed, walnuts) are associated with healthier endocannabinoid signaling, while excess omega-6 intake may contribute to imbalance. The Mediterranean dietary pattern is the most studied in this context.

Sources

• Russo, E.B. (2004). “Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?” Neuroendocrinology Letters, 25(1-2), 31–39. PMID: 15159679
• Russo, E.B. (2016). “Clinical endocannabinoid deficiency reconsidered: current research supports the theory in migraine, fibromyalgia, irritable bowel, and other treatment-resistant syndromes.” Cannabis and Cannabinoid Research, 1(1), 154–165. PMC: PMC5576607. DOI: 10.1089/can.2016.0009
• McPartland, J.M., Guy, G.W., & Di Marzo, V. (2014). “Care and feeding of the endocannabinoid system: a systematic review of potential clinical interventions that upregulate the endocannabinoid system.” PLOS ONE, 9(3), e89566. PMC: PMC3951193
• Sarchielli, P. et al. (2007). “Endocannabinoids in chronic migraine: CSF findings suggest a system failure.” Neuropsychopharmacology, 32(6), 1384–1390. PMID: 17047667
• Rhyne, D.N. et al. (2016). “Effects of medical marijuana on migraine headache frequency in an adult population.” Pharmacotherapy, 36(5), 505–510. PMID: 26749064
• García-Domínguez, M. (2025). “Role of the endocannabinoid system in fibromyalgia.” Frontiers in Medicine. PMC: PMC12025820
• Russell, L. et al. (2024). “Nutrition, endocannabinoids, and the use of cannabis: an overview for the nutrition clinician.” Nutrition in Clinical Practice, 39(4), 815–823. DOI: 10.1002/ncp.11148
• Hindocha, C. et al. (2024). “Peripheral endocannabinoids in major depressive disorder and alcohol use disorder: a systematic review.” BMC Psychiatry, 24, 551. DOI: 10.1186/s12888-024-05986-8
• Fuss, J. et al. (2015). “A runner’s high depends on cannabinoid receptors in mice.” PNAS, 112(42), 13105–13108. PMID: 26438875